Skip to main content
Logo Lanthio
  • Introduction
  • Programs
  • Technology
  • Partnering
  • Publications
  • News
  • About us
☰ Show/Hide Menu

News

You are here

  1. Home
  2. News
Date
Title
  1. 08/05/2021
    Scientific Meetings 2021
  2. 08/05/2021
    Partnering Meetings 2021
  3. 16/11/2020
    Today, the shares of Lanthio Pharma B.V., owned by MorphoSys AG, have been purchased by Lanthio Participatie B.V.
  4. 19/12/2017
    Lanthio Pharma and MorphoSys scientists publish lanthipeptide phage display in Nature Communications
  5. 19/05/2017
    MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
  6. 21/02/2017
    MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
  7. 19/09/2016
    Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys’s Dutch Lanthipeptide Subsidiary
  8. 07/05/2015
    MorphoSys Acquires Lanthio Pharma
  9. 21/11/2014
    Lanthio Pharma Receives Gouden KIEM Award as Dutch Chemical Start-up of the Year
  10. 15/10/2014
    MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
  11. 18/06/2014
    Lanthio Pharma announces change of CEO
  12. 21/05/2014
    Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis
  13. 01/09/2013
    Lanthio Pharma receives European Grant
  14. 26/11/2012
    Lanthio Pharma announces technology alliance with MorphoSys AG and secures series A financing
  15. 08/05/2012
    Lanthio Pharma receives grants from Samenwerkingsverband Noord Nederland and province of Groningen

Pages

  • 1
  • 2
  • © 2022 Lanthio Pharma
  • Imprint
  • Privacy Policy

Address
Lanthio Pharma BV
PO Box 719, 9700 AS Groningen
Rozenburglaan 13 B, 9727 DL Groningen
The Netherlands
Phone: +31 50 30 50 240
E-Mail: info@lanthiopharma.com

  • Introduction
  • Programs
  • Technology
  • Partnering
  • Publications
  • News
  • About us